The Rabbit Polyclonal anti-NUB1 antibody (ABIN7216142) specifically detects NUB1 in WB, IHC, ELISA and IF.
The antibody is reactive with Human, Mouse and Monkey samples.
Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB 1:500-1:2000,IHC 1:100-1:300,ELISA 1:20000,IF 1:50-200
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
Liquid in PBS containing 50 % glycerol, 0.5 % BSA and 0.02 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C
Storage Comment
Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.
Expiry Date
12 months
Target
NUB1
(Negative Regulator of Ubiquitin-Like Proteins 1 (NUB1))
Alternative Name
NUB1
Background
NUB1, NYREN18, NEDD8 µLtimate buster 1, Negative regulator of ubiquitin-like proteins 1, Renal carcinoma antigen NY-REN-18NUB1 encodes a protein that functions as a negative regulator of NEDD8, a ubiquitin-like protein that conjugates with cullin family members in order to regulate vital biological events. Negative regulator of ubiquitin like proteins 1 encoded by NUB1 regulates the NEDD8 conjugation system post-transcriptionally by recruiting NEDD8 and its conjugates to the proteasome for degradation. Negative regulator of ubiquitin like proteins 1 interacts with the product of the AIPL1 gene, which is associated with Leber congenital amaurosis, an inherited retinopathy, and mutations in that gene can abolish interaction with negative regulator of ubiquitin like proteins 1, which may contribute to the pathogenesis. Negative regulator of ubiquitin like proteins 1 is also known to accumulate in Lewy bodies in Parkinson's disease and dementia with Lewy bodies, and in glial cytoplasmic inclusions in multiple system atrophy, with this abnormal accumulation being specific to alpha-synucleinopathy lesions. Alternative splicing of NUB1 results in multiple transcript variants.